Human Clinical Trial Begins For Revolutionary DNA Search And Replace Gene Editor

A new chapter in genetic medicine has officially begun, as the first patient has been dosed in a clinical trial using prime editing to treat Wilson disease. This milestone marks the first time this high-precision gene editing technology has been deployed directly inside a human body, signaling a potential shift toward curative, one-time treatments for previously unmanageable genetic conditions.

Prime editing, often described as a molecular “search-and-replace” tool for the genome, was introduced in 2019 to overcome the limitations of traditional CRISPR-Cas9 methods. While classic CRISPR functions by cutting through both strands of a DNA helix, which can sometimes lead to unintended genomic damage, prime editing acts with greater subtlety. It utilizes a guide molecule to steer the machinery to a specific location, where it nicks only one strand of DNA and uses an enzyme to write in new, corrected genetic instructions. Experts estimate that this approach could theoretically address nearly 89 percent of the genetic variants linked to human disease.

Targeting Wilson Disease In Vivo

The current trial, led by the Cambridge-based firm Prime Medicine, focuses on Wilson disease, a condition characterized by a faulty gene that prevents the liver from properly processing copper. The resulting buildup of the metal causes progressive damage to the liver and neurological system. By delivering the prime editor directly into the bloodstream via lipid nanoparticles, the researchers aim to correct the underlying genetic mutation within liver cells. Mohammed Asmal, the company’s chief medical officer, noted that the therapy carries the promise of a curative intervention administered before permanent organ or brain damage can occur.

While the first patient received their dose earlier this month, the medical community will have to wait until next year for preliminary safety and efficacy data. If successful, the treatment—known as PM577a—would represent a significant improvement over the current standard of care, which requires patients to adhere to a lifelong regimen of medication.

Evolution of Genetic Correction

This development follows a banner year for gene therapy, which saw the 2024 regulatory approval of Casgevy, the first treatment to use CRISPR-Cas9 for blood disorders. However, the field has rapidly moved toward more precise alternatives. Base editing, which allows for the swap of individual DNA letters without breaking the double helix, has already shown clinical promise, including in the high-profile treatment of a young child last year.

Prime editing is viewed as the next step in this progression. Its versatility is significant because it can perform a wider array of edits than base editing, including insertions and deletions. Researchers at Prime Medicine previously demonstrated the technology’s potential in a study involving chronic granulomatous disease, where they successfully restored function to immune cells in patient samples. Although the company shifted its focus away from that specific ex vivo approach—which required complex, personalized cell manufacturing—to prioritize in vivo delivery, the proof of concept paved the way for the current Wilson disease trial.

Looking Ahead

Early data from preclinical studies provide a optimistic baseline. Experiments in non-human primates showed that a single infusion could edit roughly half of the targeted liver cells, while studies in mice resulted in an 80 percent correction rate with minimal off-target effects. These results were presented at the 2024 American Association for the Study of Liver Diseases, though they are currently awaiting formal peer-reviewed publication.

For now, the focus remains on the safety and long-term viability of the intervention. Should this trial meet its primary goals, it could establish a modular platform for treating a variety of other genetic disorders by simply swapping the RNA instructions used by the prime editor. As Prime Medicine CEO Allan Reine suggested, the current trial targets a prevalent mutation in the U.S. and Europe, but the underlying system holds the potential to be adapted for diverse patient populations worldwide.